AbbVie reports positive Phase 3 results for etentamig in relapsed/refractory multiple myeloma
AbbVie announced that its dual-specific T-cell engager etentamig improved response rates and progression-free survival in heavily pre-treated multiple myeloma, with low CRS and infection rates.